Interview with the President and CEO: Codex DNA, Inc. (NASDAQ:DNAY)
Todd R. Nelson,Ph.D., has served as the President, Chief Executive Officer and a member of the board of directors of Codex DNA, Inc. since July 2018. Prior to joining the company, Dr. Nelson served as the Chief Executive Officer of several life science companies through expansive phases of financial and commercial growth. From December 2014 to October 2017, Dr. Nelson served as Chief Executive Officer of DiscoverX Corporation, a leading developer and manufacturer of reagents intended for drug discovery. From September 2011 to October 2014, Dr. Nelson served as Chief Executive Officer of MP Biomedicals, LLC, a global manufacturer and distributor of products and services for the life science, fine chemicals, diagnostics and dosimetry markets. From June 2007 to January 2011, Dr. Nelson served as Chief Executive Officer of eBioscience, Inc., a manufacturer and distributor of immunology reagents used in pharmaceutical research. Dr. Nelson also previously served as Vice President of Global Corporate Development and Strategy at Life Technologies (now Thermo Fisher Scientific), as First Vice President Global Securities and Economics at Merrill Lynch & Co., and as Global Head of Life Sciences at RBC Capital Markets, LLC. Dr. Nelson currently serves on the board of directors of Tonbo Biosciences Corporation and TCRx Corporation. Dr. Nelson received a B.A. in Psychology, a Ph.D. in Philosophy from the University of Minnesota and an MBA in Finance from the Carlson School of Business at the University of Minnesota. Dr. Nelson also completed clinical fellowship training at Mayo Clinic in human genetics and laboratory medicine from 1996 to 1998. Profile
Word count: 1,921
TWST: Please start with a brief introduction to Codex DNA and a little bit about your history with the company?